A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

NCT04521231 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

281

Enrollment

INDUSTRY

Sponsor class

Conditions

B Cell Precursor Acute Lymphoblastic Leukemia

Interventions

DRUG: Blinatumomab

Sponsor

Amgen

Collaborators

[object Object]